leisure time -WSS

leisure time

author：focus 2025-10-02 18:05:55 - browse：131

1:56Threshold Glass Jar Candles sold exclusively by Target.U.S. Consumer Product Safety Commission

Target has recalled another 2.2 million of its Threshold candles due to reports of candle jars breaking or cracking during use.

In May, the United States Consumer Product Safety Commission announced the recall of nearly 5 million Target Threshold candle products after the retailer received 137 reports of it breaking or cracking during use.

Now, the Minnesota-based retailer has recalled another 2.2 million candles, the CPC announced Thursday.

"Target received 19 reports of the candle jar breaking or cracking during use, resulting in one minor injury," the agency stated.

MORE: General Motors recalls over 600K cars due to car seat safety issue

Six injuries were reported in the previous recall, including lacerations and severe burns, according to the CPSC.

"This recall involves certain Threshold Glass Jar 5.5 ounce 1-Wick, 14 ounce 3-Wick and 20 ounce 3-Wick Candles in multiple scents," the CPSC stated. "The recalled item numbers are printed on the bottom of the glass jars."

PHOTO: Threshold Glass Jar Candles sold exclusively by Target. — Threshold Glass Jar Candles sold exclusively by Target.U.S. Consumer Product Safety Commission

Click here for a full list of the recalled product details and item numbers.

The CPSC urged consumers to stop using the recalled candles immediately and return them to Target for a refund. Customers can also contact Target for a prepaid return label to send them back by mail.

The candles, which were manufactured in Vietnam, were sold at Target stores nationwide as well as online from August 2019 through March 2023 for between $3 and $20.

An earlier version of this story was originally published May 19, 2023.

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Stopping antidepressants leads to symptoms for 1 in 6 patients

WSS

Sutter Health’s antitrust win overturned by appeals court

Unique patient identifier: Experts argue the benefits, pitfalls

Why Novartis is going to walk from its acquisition of MorphoSys

AI gets buy

The CDC's new social media misinformation war

Readout Newsletter: Amgen, Regeneron, BGI Group and more

focus

leisure time

MORE: General Motors recalls over 600K cars due to car seat safety issue

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Drug repurposing or repositioning? The language matters

Top private equity targets in 2023: cardiology, clinical trials, lasers

Bright Health sells Medicare Advantage business to Molina

Take antibiotics after sex, CDC recommends for certain risk groups

Drug repurposing or repositioning? The language matters

Medicare Advantage plans can’t deny care with AI, CMS warns

Continuity nursing helped my family in our darkest PICU moments

Adopting new red light myopia treatments may be short

Wikipedia

A single Democrat is willing to weaken Medicare negotiation power

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Bernie brings in new pharma CEOs to talk drug prices

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Data don't support strong claims for Covid

focus

entertainment

focus

hotspot